Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All remdesivir studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Severe case 7% Improvement Relative Risk Remdesivir for COVID-19  Bavaro et al.  LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? Retrospective 331 patients in Italy (July 2021 - March 2022) Lower severe cases with remdesivir (p=0.00099) c19early.org Bavaro et al., Viruses, May 2023 Favors remdesivir Favors control

Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study

Bavaro et al., Viruses, doi:10.3390/v15051199
May 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Retrospective 331 hospitalized COVID-19 patients in Italy, showing lower progression with remdesivir. Combination therapy with mAbs was more effective, and improved results were seen for immunocompromised patients.
Gérard, Wu, Zhou show significantly increased risk of acute kidney injury with remdesivir.
risk of severe case, 7.0% lower, RR 0.93, p < 0.001, treatment 120, control 211, propensity score weighting.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bavaro et al., 19 May 2023, retrospective, Italy, peer-reviewed, median age 75.0, 27 authors, study period 1 July, 2021 - 15 March, 2022. Contact: davidebavaro@gmail.com (corresponding author).
This PaperRemdesivirAll
Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study
Davide Fiore Bavaro, Lucia Diella, Alessandra Belati, Giuliana Metrangolo, Laura De Santis, Vito Spada, Michele Camporeale, Angelo Dargenio, Gaetano Brindicci, Flavia Balena, Deborah Fiordelisi, Fabio Signorile, Giacomo Loseto, Crescenza Pasciolla, Carla Minoia, Immacolata Attolico, Tommasina Perrone, Simona Simone, Maria Rendina, Nicoletta Giovine, Francesco Di Gennaro, Pellegrino Musto, Attilio Guarini, Alfredo Di Leo, Loreto Gesualdo, Maria Dell’aera, Annalisa Saracino
Viruses, doi:10.3390/v15051199
Introduction: Remdesivir (REM) and monoclonal antibodies (mAbs) could alleviate severe COVID-19 in at-risk outpatients. However, data on their use in hospitalized patients, particularly in elderly or immunocompromised hosts, are lacking. Methods: All consecutive patients hospitalized with COVID-19 at our unit from 1 July 2021 to 15 March 2022 were retrospectively enrolled. The primary outcome was the progression to severe COVID-19 (P/F < 200). Descriptive statistics, a Cox univariate-multivariate model, and an inverse probability treatment-weighted (IPTW) analysis were performed. Results: Overall, 331 subjects were included; their median (q1-q3) age was 71 (51-80) years, and they were males in 52% of the cases. Of them, 78 (23%) developed severe COVID-19. All-cause in-hospital mortality was 14%; it was higher in those with disease progression (36% vs. 7%, p < 0.001). REM and mAbs resulted in a 7% (95%CI = 3-11%) and 14% (95%CI = 3-25%) reduction in the risk of severe COVID-19, respectively, after adjusting the analysis with the IPTW. In addition, by evaluating only immunocompromised hosts, the combination of REM and mAbs was associated with a significantly lower incidence of severe COVID-19 (aHR = 0.06, 95%CI = 0.02-0.77) when compared with monotherapy. Conclusions: REM and mAbs may reduce the risk of COVID-19 progression in hospitalized patients. Importantly, in immunocompromised hosts, the combination of mAbs and REM may be beneficial.
Supplementary Materials: The following supporting information can be downloaded at: https: //www.mdpi.com/article/10.3390/v15051199/s1, Table S1 : Standardized differences of variables used to generate the IPTW model. Institutional Review Board Statement: The study was conducted with the formal approval of the ethics committee of the University Hospital Policlinico (Bari, Italy) (Study Code: 6357). The study was Conflicts of Interest: The authors declare no conflict of interest.
References
Activ-3/Tico Bamlanivimab, Group; Lundgren, Grund, Barkauskas, Holland et al., Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels: A Randomized Controlled Trial, Ann. Intern. Med, doi:10.7326/M21-3507
Antonelli, Penfold, Merino, Sudre, Molteni et al., Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: A prospective, community-based, nested, case-control study, Lancet Infect. Dis, doi:10.1016/S1473-3099(21)00460-6
Austin, Stuart, Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies, Stat. Med, doi:10.1002/sim.6607
Balena, Bavaro, Fabrizio, Bottalico, Calamo et al., Tocilizumab and corticosteroids for COVID-19 treatment in elderly patients, J. Gerontol. Geriatr, doi:10.36150/2499-6564-283
Bansal, Goyal, Cusick, Lahan, Dhaliwal et al., Hydroxychloroquine: A comprehensive review and its controversial role in coronavirus disease 2019, Ann. Med
Bartoletti, Azap, Barac, Bussini, Ergonul et al., ESCMID COVID-19 living guidelines: Drug treatment and clinical management, Clin. Microbiol. Infect
Bavaro, Belati, Diella, Poli, Calamo et al., Prompt and Appropriate Antimicrobial Therapy Improves Outcomes of NDM-Producing and KPC-Producing Klebsiella pneumoniae Bloodstream Infections in Patients Hospitalized for COVID-19: A Comparative Retrospective Case-Series, Antibiotics, doi:10.3390/antibiotics11111519
Bernal, Gomes Da Silva, Musungaie, Kovalchuk, Gonzalez et al., Molnupiravir for Oral Treatment of COVID-19 in Nonhospitalized Patients, N. Engl. J. Med, doi:10.1056/NEJMoa2116044
Bharadwaj, El-Kafrawy, Alandijany, Bajrai, Shah et al., Structure-Based Identification of Natural Products as SARS-CoV-2 Mpro Antagonist from Echinacea angustifolia Using Computational Approaches, Viruses, doi:10.3390/v13020305
Brookhart, Schneeweiss, Rothman, Glynn, Avorn et al., Variable selection for propensity score models, Am. J. Epidemiol, doi:10.1093/aje/kwj149
Chamlagain, Shah, Sharma Paudel, Dhital, Kandel, Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review, Interdiscip. Perspect. Infect. Dis, doi:10.1155/2021/8903435
Cox, Peacock, Harvey, Hughes, Wright, COVID-19 Genomics UK (COG-UK) Consortium
Damanti, Ramirez, Bozzolo, Da Prat, Di Lucca et al., Frailty as a predictor of mortality in COVID-19 patients receiving CPAP for respiratory insufficiency, Aging Clin. Exp. Res, doi:10.1007/s40520-021-02070-z
Falcone, Suardi, Tiseo, Barbieri, Giusti et al., Early Use of Remdesivir and Risk of Disease Progression in Hospitalized Patients with Mild to Moderate COVID-19, Clin. Ther, doi:10.1016/j.clinthera.2022.01.007
Falcone, Suardi, Tiseo, Galfo, Occhineri et al., Superinfections caused by carbapenem-resistant Enterobacterales in hospitalized patients with COVID-19: A multicentre observational study from Italy (CREVID Study), doi:10.1093/jacamr/dlac064
Falcone, Tiseo, Giordano, Leonildi, Menichini et al., Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: A prospective observational study, J. Antimicrob. Chemother, doi:10.1093/jac/dkaa530
Ford, Simmons, Karmarkar, Yoke, Braimah et al., Successful treatment of prolonged, severe COVID-19 lower respiratory tract disease in a B-cell ALL patient with an extended course of remdesivir and nirmatrelvir/ritonavir, Clin. Infect. Dis, doi:10.1093/cid/ciac868
Gandhi, Klein, Robertson, Peña-Hernández, Lin et al., De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: A case report, Nat. Commun, doi:10.1038/s41467-022-29104-y
Gidari, Sabbatini, Schiaroli, Bastianelli, Pierucci et al., The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro, Microorganisms, doi:10.3390/microorganisms10071475
Goletti, Cantini, Baricitinib Therapy in COVID-19 Pneumonia-An Unmet Need Fulfilled, N. Engl. J. Med, doi:10.1056/NEJMe2034982
Gottlieb, Vaca, Paredes, Mera, Webb et al., Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients, N. Engl. J. Med, doi:10.1056/NEJMoa2116846
Helleberg, Niemann, Moestrup, Kirk, Lebech et al., Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy, J. Infect. Dis, doi:10.1093/infdis/jiaa446
Horby, Lim, Emberson, Mafham, Bell et al., Dexamethasone in Hospitalized Patients with COVID-19, N. Engl. J. Med, doi:10.1056/NEJMoa2021436
Hussain Alsayed, Saheb Sharif-Askari, Saheb Sharif-Askari, Hussain, Hamid et al., Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study, PLoS ONE, doi:10.1371/journal.pone.0258643
Komagamine, Yabuki, Yoshihara, Tanaka, The effect of casirivimab with imdevimab on disease progression in nonsevere COVID-19 patients in a single hospital in Japan, J. Gen. Fam. Med, doi:10.1002/jgf2.516
Martinez, Chen, Choi, Hwang, Navarathna et al., Extended Remdesivir Infusion for Persistent Coronavirus Disease, Infection. Open Forum Infect. Dis
Milam, Doan, Childress, Durham, Evaluation of Monoclonal Antibodies in Preventing Hospitalizations, Emergency Department Visits, and Mortality in High-Risk COVID-19 Patients, J. Pharm. Technol, doi:10.1177/87551225221080027
Montazersaheb, Hosseiniyan Khatibi, Hejazi, Tarhriz, Farjami et al., COVID-19 infection: An overview on cytokine storm and related interventions, Virol. J, doi:10.1186/s12985-022-01814-1
Ozer, Goksu, Conception, Ulker, Balderas et al., Effectiveness and safety of Ivermectin in COVID-19 patients: A prospective study at a safety-net hospital, J. Med. Virol, doi:10.1002/jmv.27469
Pagano, Salmanton-García, Marchesi, Busca, Corradini et al., COVID-19 infection in adult patients with hematological malignancies: A European Hematology Association Survey (EPICOVIDEHA), J. Hematol. Oncol, doi:10.1186/s13045-021-01177-0
Paranjape, Husain, Priestley, Koonjah, Watts et al., Early Use of Remdesivir in Patients Hospitalized With COVID-19 Improves Clinical Outcomes: A Retrospective Observational Study, Infect. Dis. Clin. Pract. 2021, doi:10.1097/IPC.0000000000001023
Patel, Patel, Barvaliya, Saurabh, Bhalla et al., Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials, J. Infect. Public Health, doi:10.1016/j.jiph.2021.03.015
Shafran, Shafran, Ben-Zvi, Sofer, Sheena et al., Secondary bacterial infection in COVID-19 patients is a stronger predictor for death compared to influenza patients, Sci. Rep
Takahashi, Wakita, Ishihara, Okazaki, Ito et al., Short-course remdesivir for healthcareassociated COVID-19: Case series from a non-acute care hospital, J. Infect. Chemother, doi:10.1016/j.jiac.2022.08.025
Takashita, Kinoshita, Yamayoshi, Sakai-Tagawa, Fujisaki et al., Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2, N. Engl. J. Med, doi:10.1056/NEJMc2201933
Wada, Nakamori, Maruyama, Shimazu, Saito et al., Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infection, Exp. Hematol. Oncol, doi:10.1186/s40164-022-00307-9
Wang, Yang, Chinese herbal medicine: Fighting SARS-CoV-2 infection on all fronts, J. Ethnopharmacol, doi:10.1016/j.jep.2021.113869
Wang, Yang, Song, Oral GS-441524 derivatives: Next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase, Front. Immunol, doi:10.3389/fimmu.2022.1015355
Wang, Zhang, Du, Du, Zhao et al., Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial, Lancet, doi:10.1016/S0140-6736(20)31022-9
Westblade, Simon, Satlin, Bacterial Coinfections in Coronavirus Disease, Trends Microbiol, doi:10.1016/j.tim.2021.03.018
Willett, Thomson, Gupta, Peacock, SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies, Nature reviews. Microbiology, doi:10.1038/s41579-022-00809-7
Yang, Wang, Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer, Biomedicines, doi:10.3390/biomedicines9060689
Zazzara, Bellieni, Calvani, Coelho-Junior, Picca et al., Inflammaging at the Time of COVID-19, Clin. Geriatr. Med, doi:10.1016/j.cger.2022.03.003
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit